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1  Introduction 
1.1 Biology of IL-22 
1.1.1 The unusual cytokine IL-22 
Interleukins describe a subgroup of cytokines first seen to be expressed by leukocytes that 
are crucial for the function of the immune system. Interleukin-22 (IL-22) – discovered in 
2000 and originally termed IL-10-related T cell derived inducible factor – is a member of the 
IL-10 family which also comprises IL-10, IL-19, IL-20, IL-24, IL-26 and type III interferons 
(IFNl) (Ouyang, et al. 2011). IL-22 can be regarded as an unusual interleukin since it does 
not regulate the function of immune cells directly (Wolk, et al. 2004). In fact, its designation 
as an “interleukin” can be regarded as a misnomer since the corresponding IL-22 receptor 
a chain 1 (IL-22-Ra1) is not expressed on leukocytes, meaning that the cytokine cannot 
function as a mediator between leukocytes (reviewed in: Hernandez, et al. 2018). Instead, 
IL-22-Ra1 is constitutively expressed on non-hematopoietic cells and facilitates cross-talk 
between hematopoietic and non-hematopoietic cells. IL-22 thus targets cells at external 
barriers, which includes mainly tissues of the skin, digestive tract and respiratory systems, 
but also cells of the liver, pancreas and kidney (reviewed in: Sabat, et al. 2014).  
The exact functions of IL-22 seem to be dependent on the context of its induction as well as 
its localization. IL-22 controls a gene expression program linked to epithelial defense, 
regeneration and repair (reviewed in: Rutz, et al. 2013). As such, IL-22 increases 
proliferation, inhibits differentiation and protects its target cells against damage – effects 
that are not shared by other cytokines (reviewed in: Sabat, et al. 2014). In many epithelial 
cells IL-22 also induces the production of antibacterial proteins, acting in conjunction with 
cytokines such as IL-17, tumor necrosis factor (TNF) or IL-1b.  
1.1.2 Cellular sources of IL-22 
The precise cellular sources of IL-22 in both physiological and pathological situations are 
often unidentified and most likely vary depending on the context (reviewed in: Sabat, et al. 
2014). It is known that IL-22 is almost exclusively produced by cells of the immune system 
(Wolk, et al. 2004). Though initially thought to be secreted primarily by a subset of CD11c+ 
mononuclear phagocytes (Pickert, et al. 2009, Zheng, et al. 2008), IL-22 is now mostly 
regarded as a cytokine produced by CD4+ T helper cells, gd T cells, group 3 innate 
lymphoid cells (ILC3 and LTi), and CD1d-restricted T cells (iNKTs) (Dudakov, et al. 2015, 
Sanos, et al. 2009, Takatori, et al. 2009). In addition, it has been shown that under 
inflammatory conditions cells from the myeloid compartment can sometimes produce IL-22, 
namely, neutrophils, monocytes, dendritic cells, and macrophages (Kulkarni, et al. 2014, 
Zheng, et al. 2008, Zindl, et al. 2013).  
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Figure 1: Cellular sources of IL-22 in humans (modified from: Lim and Savan 2014). 
 
The first identified T helper cell subset to produce IL-22 were Th1 cells. Around 35 % of all 
IL-22+CD4+ cells in peripheral human blood are estimated to be Th1 cells (Duhen, et al. 
2009). This is consistent with the finding that IL-22 production in human T cells is highly 
correlated with IFNg and T-bet, the Th1 master transcription factor (Volpe, et al. 2009). In 
human Th1 cells, IL-22 production is primarily induced by IL-12 – alone or in synergy with 
IL-18 (Gurney 2004). In comparison, murine IL-22 secretion from Th1 cells stems from 
activation by IL-12 and IL-23 (Kaczmarek, et al. 2013).  
Th17 cells also produce significant amounts of IL-22 (Chung, et al. 2006, Liang, et al. 
2006). While seen as the major source of IL-22 in mice, in human peripheral blood only 10-
18 % of IL-22-producing CD4+ T cells co-express IL-17 (Duhen, et al. 2009). Given the 
synergistic actions of IL-17 and IL-22, this co-expression can lead to notable amplifications 
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of their effects. Differentiation of naïve T cells into Th17 cells can be stimulated with IL-1b, 
IL-6 and transforming growth factor-b (TGFb) (Ivanov, et al. 2006), and IL-21 and IL-23 act 
to further maintain and stabilize Th17 cells. Interestingly, IL-1b, IL-6 and IL-23 do not only 
promote Th17 differentiation, but also IL-22 expression. IL-21 and TGFb can potently inhibit 
IL-22 in murine Th17 cells (Zheng, et al. 2007).  
However, the majority of Th cells producing IL-22 in peripheral human blood, between 37 % 
and 63 %, do not co-express IL-17 nor IFNg (Duhen, et al. 2009). This separate subset of 
Th cells has been defined as Th22 cells. New evidence suggests that Th22 cells 
demonstrate plasticity toward both Th1 and Th2 cells but develop independently of the 
Th17 lineage (Plank, et al. 2017). Th22 differentiation is stimulated by IL-6, IL-21 and 
TNFa, and vitamin D leads to further increases in IL-22 production (Fujita, et al. 2009). Of 
note, the Th22 subpopulation does not express T-bet and only low levels of the retinoic 
acid-related orphan receptor gt (RORgt) (Duhen, et al. 2009, Trifari, et al. 2009). 
Furthermore, it has been shown that the aryl hydrocarbon receptor (AhR) and STAT3 play 
an important role in Th22 differentiation (Yeste, et al. 2014). Whether this separate Th22 
lineage correspondingly exists in mice is still investigated (Liang, et al. 2006). 
Other T cells such as CD8+ T cells, gd T cells and natural killer T (NKT) cells have also 
been discovered to produce IL-22, particularly upon activation by IL-23 (Witte, et al. 2010). 
Mirroring their CD4+ counterparts, human CD8+ cytotoxic T cells have been categorized 
into subsets secreting either IL-17 and IL-22 (Tc17) or only IL-22 (Tc22) (Rutz, et al. 2013). 
Differentiation from naïve CD8+ T cells to Tc22 has been shown to be inducible by IL-21 via 
phosphorylation of STAT1, 3 and 5. Similar to their Th cell counterparts, TGFb inhibits IL-
22 but induces IL-17 secretion from Tc17 and Tc22 cells (Liu, et al. 2011).  
More recently, innate T cell populations were identified to secrete IL-22 at epithelial sites. In 
particular, gd T cells have been shown to produce IL-22 upon IL-23 or RORgt stimulation as 
well as activation of innate Toll-like receptors (TLRs) (Eken, et al. 2014, Tominaga, et al. 
2013). Because of their constitutive expression of the IL-23 receptor (IL-23R) gd T cells can 
instantly react to IL-23 stimulation with expression of IL-17 and IL-22 (Martin, et al. 2009). 
In murine settings, most gd T cells co-express IL-17 and RORgt, underlining the correlation 
between IL-17 and IL-22. In humans, this link is again less pronounced and cytokine 
secretion in human gd T cells is similar to that of Th cells. Another type of innate T cells, 
natural killer T (NKT) cells, can also produce IL-17 and IL-22. Interestingly, the transcription 
factor T-bet regulates the terminal differentiation and hemostasis of NKT cells (Koyama, et 
al. 2008). In addition, human invariant NKT (iNKT) cells have been shown to produce IL-22 
via AhR in response to stimulation with IL-1b and IL-23 (Moreira-Teixeira, et al. 2011).  
Introduction 
4 
Group 3 ILCs are regarded as an increasingly important source of IL-22, especially at 
mucosal sites such as the GI tract. They are thought to be the innate counterpart of Th17 
and Th22 cells and are defined by their capacity to produce IL-17 or IL-22. Sharing the 
common transcription factor RORgt they comprise ILC3s and lymphoid-tissue inducer cells 
(LTis). They express IL-23R and secretion of IL-17 and IL-22 can be stimulated by IL-1b 
and IL-23 (Cella, et al. 2010).  
Importantly, differences between IL-22 production in humans and mice have been shown. 
Murine IL-22 mostly originates from Th17 cells, while mouse Th1 cells tend to express IL-
22 weakly (Liang, et al. 2006). In contrast, in humans significant amounts of IL-22 are 
secreted by each subset, that is Th1, Th17 and Th22 cells alike (reviewed in: Ouyang, et al. 
2011). Th22 cells have been shown to release IL-22 without IL-17 and IFNg in humans, but 
not in mice. This difference is linked to TGFb, which increases IL-17 but inhibits IL-22 
production by human T cells.  
Table 1: IL-22-producing cells in humans (murine if different) 
Cell 
type 
Specific surface 
markers 
Other 
cytokines 
produced 
Cytokines 
inducing     
IL-22 
Transcription 
factor for      
IL-22 induction 
References 
Th1 CD3+CD4+ IFNg,   IL-
2, TNF 
IL-12, IL-18 
(IL-12, IL-23) 
STAT4 (Gurney 2004) 
Th17 CD3+CD4+ IL-17, IL-
21, IL-26 
IL-1b, IL-6, 
IL-21, IL-23, 
TGFb 
STAT3, RORgt, 
Notch, AhR 
(Ikeda, et al. 2014) 
Th22 CD3+CD4+ - IL-6, TNFa  
(IL-6, IL-21) 
STAT3, AhR (Duhen, et al. 
2009), (Yeste, et al. 
2014) 
Tc17 CD3+CD8+ IFNg, IL-
17 
unk. 
(IL-23) 
STAT3 (Ciric, et al. 2009) 
Tc22 CD3+CD8+ - IL-21 
(unk.) 
STAT1, 3, 5 (Liu, et al. 2011) 
gd T  CD3+gdTCR+ IGF-1, IL-
17, IL-21 
IL-23 
(IL-1b, IL-23) 
STAT3, AhR, 
RORgt 
(Martin, et al. 2009), 
(Sutton, et al. 2009) 
NK CD3-CD56+CD16+ IFNg, 
TNF, GM-
CSF 
IL-2, IL-12, 
IL-18 
STAT4 (Cella, et al. 2009) 
NKT CD3-
CD8+CD56+CD16+ 
 IL-1b, IL-23  
(CD3/28, IL-
1b, IL-2, IL-
23) 
STAT3, AhR, 
RORgt 
(Moreira-Teixeira, 
et al. 2011), (Goto, 
et al. 2009) 
LTi CD117+NKp46- IL-17 IL-23 STAT3 (Takatori, et al. 
2009), (Crellin, et 
al. 2010) 
NCR+ 
ILC3 
CD117+NKp46+ - IL-1b, IL-23 
(IL-23) 
STAT3, TBX21, 
Notch 
(Cella, et al. 2010), 
(Teunissen, et al. 
2014) 
NCR- 
ILC3 
CD117+NKp46- - IL-1a, IL-1b, 
IL-23 
 (Hernandez, et al. 
2015) 
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1.1.3 Stimuli required for IL-22 production 
IL-22 secretion can be stimulated by several factors, including activation of the transcription 
factor AhR (Veldhoen, et al. 2008). AhR agonists include endogenous molecules such as 
kynurenine or FICZ (Mezrich, et al. 2010) and exogenous molecules such as dioxin (Ema, 
et al. 1994). Other stimuli include the activation of Toll-like receptors such as TLR4 
(Tominaga, et al. 2013) or IL-23 binding to the IL-23 receptor (IL-23-R) (Zheng, et al. 2007). 
The transcription factor RORgt is necessary for Th17 differentiation in humans and mice 
(Ivanov, et al. 2006). IL-22 expression in Th17 is mainly regulated via the transcription 
factor AhR (Veldhoen, et al. 2008). 
Interestingly, IL-22 has also been described to induce the expression of proteins that lead 
to a positive feedback loop, thereby further amplifying its production and effects (reviewed 
in: Sabat, et al. 2014). For example, the Notch pathway leads to activation of endogenous 
AhR ligands, which amplifies IL-22 effects (Alam, et al. 2010).  
1.1.4 Target cells of IL-22  
IL-22 is secreted predominantly by immune cells, yet its receptor is restrictively expressed 
by non-hematopoietic cells. IL-22 transmits its cellular effects through the heterodimeric IL-
22 receptor complex (IL-22-R) consisting of IL-22-Ra1 and IL-10-R2 (Kotenko, et al. 2001, 
Xie, et al. 2000). Since the R2 subunit of the receptor complex is expressed ubiquitously, 
the cellular sensitivity towards IL-22 is controlled solely by the expression of IL-22-Ra1 
(Wolk, et al. 2004). In line with their lack of responsiveness to IL-22 it has been shown that 
hematopoietic cells do not express IL-22-Ra1 (Wolk, et al. 2002, Wolk, et al. 2004, Wolk, et 
al. 2008).  
The principal physiological target of IL-22 seems to be epithelial cells (Boniface, et al. 
2005) as cells of anatomical barriers like the skin and tissues of both gastrointestinal and 
respiratory tract are sensitive to IL-22. So far, the functional receptor for IL-22 has been 
found on the surface of bronchial epithelial cells (Aujla, et al. 2008), hepatocytes (Radaeva, 
et al. 2004), keratinocytes (Wolk, et al. 2004, Wolk, et al. 2006), intestinal epithelial cells 
(Nagalakshmi, et al. 2004), pancreatic cells (Aggarwal, et al. 2001, Shioya, et al. 2008), 
and thymic epithelial cells (Dudakov, et al. 2012). Other target cells include specific tissue-
resident stem cells, which possibly contributes to its protective properties against damage 
in several tissues (Feng, et al. 2012, Hanash, et al. 2012). 
The regulation of the IL-22-Ra1 remains only partially understood (reviewed in: Lim and 
Savan 2014). In keratinocytes, it has been shown that IFNa stimulation increases IL-22-
Ra1 expression (Tohyama, et al. 2009). Similarly, IFNg and TNF appeared to upregulate 
IL-22-Ra1 expression in both keratinocytes and dermal fibroblasts (Wolk, et al. 2009, Wolk, 
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et al. 2004). This indicates that the presence of inflammatory cytokines might intensify the 
effects of IL-22. Repression of IL-22-Ra1 expression has been observed in a few cases, for 
example via latency-associated nuclear antigen (LANA) proteins in Kaposi’s sarcoma (Su, 
et al. 2011).  
It is important to note that both subunits of the receptor complex are shared with other 
cytokines of the IL-10 family; only the combination of IL-10-R2 and IL-22-Ra1 specifically 
mediates IL-22 signaling. IL-22-Ra1 can also associate with IL-20-R2 to mediate the effects 
of IL-20 or IL-24. IL-10-R2, on the other hand, also mediates the effects of IL-10, IL-26 as 
well as IL-28 and IL-29 (reviewed in: Ouyang, et al. 2011, Sabat 2010). 
In addition to the membrane-bound IL-22-Ra1 receptor, there exists a soluble receptor, IL-
22 binding protein (IL-22-BP), which antagonizes the actions of IL-22 (Dumoutier, et al. 
2001, Kotenko, et al. 2001). As such, IL-22 is regarded as unique among other IL-10 
cytokines as it has an endogenous inhibitor. IL-22-BP binds to IL-22 at the same binding 
site as IL-22-Ra1, but with 1.000-fold higher affinity (Jones, et al. 2008). IL-22-BP 
expression has been found in lymphocytes as well as various myeloid cell types such as 
CD103+ DCs and macrophages (Martin, et al. 2014).  
1.1.5 IL-22 signaling 
The binding of IL-22 to its receptor can be described as a two-step process. IL-22 first 
binds to its receptor subunit IL-22-Ra1 with high affinity. This association alters the 
conformation of the IL-22 protein and allows the cytokine to bind to the IL-10-R2 subunit 
(reviewed in: Sabat, et al. 2014). The attachment of IL-10-R2 to IL-22-IL-22-Ra1 stabilizes 
the complex and initiates intracellular signaling pathways. 
Intracellularly, IL-22 primarily signals through Janus kinase (JAK) and signal transducer 
and activator of transcription (STAT) molecules (Lejeune, et al. 2002). The cytoplasmic part 
of the IL-22-Ra1 subunit is associated with the JAK1 while the IL-10-R2 subunit is linked to 
the tyrosine kinase 2 (TYK2). After IL-22 binds to its full receptor, both JAK1 and TYK2 
become activated, resulting in phosphorylation of tyrosine residues of the STAT1, STAT3 
and, to a lesser extent, STAT5 proteins (Lejeune, et al. 2002, Wolk, et al. 2007). After 
phosphorylation, dimerized STAT proteins translocate into the nucleus, where they are able 
to regulate the expression of target genes by binding to responsive elements (reviewed in: 
Sabat, et al. 2014).  
Phosphorylation of STAT3 at the Tyr705 residue plays a major role in the IL-22-induced 
activation of genes (Dumoutier, et al. 2009). Strong induction of pSTAT3 through IL-22 has 
been demonstrated, for instance, in murine colonic epithelial cells as well as human colonic 
cancer cells and biopsies (Pickert, et al. 2009, Sugimoto, et al. 2008). STAT5 activation, 
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though rare, has been described for kidney cells and hepatocytes, with yet unknown 
downstream effects (Brand, et al. 2007). STAT1 activation by IL-22, while observed only in 
some cells (Wolk, et al. 2004), has recently been shown to have biological functions in the 
context of murine rotavirus infections (Hernandez, et al. 2015).  
Next to the JAK-STAT signaling, activation of mitogen-activated protein kinase (MAPK) 
pathways have been described (Kim, et al. 2014). Other designated pathways include 
activation of NF-kB, AKT, phosphoinositide 3-kinase (PI3K) and mammalian target of 
rapamycin (mTOR) (Kim, et al. 2012, Lejeune, et al. 2002, Mitra, et al. 2012).  
 
Figure 2: Signalling of IL-22 (modified from: Sabat, et al. 2014). 
1.2 Effects of IL-22 
1.2.1 Physiological effects of IL-22 
IL-22 is thought to be a homeostatic cytokine that preserves the integrity of boundary 
tissues and organs, but a clear understanding of the mechanism through which IL-22 may 
protect epithelial cells against damage and stimulate tissue repair is still missing (reviewed 
in: Hernandez, et al. 2018). In the skin, IL-22 stimulation has been shown to cause 
proliferation of keratinocytes and fibroblasts (Mitra, et al. 2012), thereby promoting wound 
healing. IL-22 can induce antimicrobial proteins like defensins and pro-inflammatory 
molecules of the S100 family in epithelial cells (Liang, et al. 2006). Further, IL-22 
stimulation upregulates matrix metalloproteinases to induce cell migration (Boniface, et al. 
2005).  
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In the gut, IL-22 has been shown to stimulate epithelial repair after physical, chemical or 
microbial damage (Monteleone, et al. 2011, Zheng, et al. 2008). IL-22 enhances intestinal 
epithelial cell migration (Brand, et al. 2006), improves healing of wounded mucosa (Pickert, 
et al. 2009) and increases expression of mucus-associated proteins (Mizoguchi 2012). H. 
pylori infections have been shown to be controlled by IL-22 (Moyat, et al. 2017). Similarly, 
IL-22 deficient mice failed to control rotavirus infections in a STAT1-dependent manner 
(Hernandez, et al. 2015). In the liver, IL-22 stimulation also increased acute phase proteins 
such as haptoglobin or serum amyloid A (Liang, et al. 2010). 
In the lung, physiological effects of IL-22 primarily include modulating immunity 
(Whittington, et al. 2004, Wolk, et al. 2004). IL-22 seems to play a protective role in the 
context of viral, bacterial and parasitic infections by promoting antimicrobial activity and 
proliferation of lung epithelium (Aujla, et al. 2008). In addition, IL-22 can protect cells in the 
lung from inflammation-induced pulmonary fibrosis through increased airway epithelial cell 
proliferation as well as transepithelial resistance to injury (Simonian, et al. 2009).  
1.2.2 Pathological effects of IL-22 
In general, IL-22 seems to play a protective role in the acute context of injury and 
inflammation. In chronic conditions, however, IL-22 can promote diseases through 
proliferation and anti-apoptosis (Eyerich, et al. 2009).  
In the skin, higher numbers of IL-22-producing T cells in lesions correlate with disease 
activity in patients with psoriasis or atopic dermatitis (Hijnen, et al. 2013). Elevated IL-22-
Ra1 expression in epidermal keratinocytes has been shown to play a role in the 
pathogenesis of psoriasis by enhancing the coordinated effects of IL-17 and IL-22 
(Tohyama, et al. 2009). Progression from acute to chronic phases of atopic dermatitis are 
also associated with a progressive activation of IL-22-producing lymphocytes (Gittler, et al. 
2012). A human anti-IL-22-mAb (fezakinumab) is currently tested as a treatment for atopic 
dermatitis, with promising preliminary results (Guttman-Yassky, et al. 2018). 
In inflammatory bowel diseases (IBDs), the role of IL-22 seems to be time dependent. IL-22 
was observed to be a protective factor in a murine model of colitis during acute 
inflammation (Zenewicz, et al. 2007). Recently, it was suggested that development of IBDs 
correlates with high levels of IL-22-BP and that successful anti-TNFa treatment may act in 
part by suppressing IL-22-BP (Pelczar, et al. 2016). Contrastingly, IL-22 can be disease-
promoting in chronic states of IBDs, as IL-22 blockage at a later stage has been shown to 
protect mice from colitis (Eken, et al. 2014). Elevated IL-22 expression in primary tissue 
was also closely linked to the severity of chronic colitis and associated with progression of 
disease (Yu, et al. 2013). 
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In the lung, patients with chronic obstructive pulmonary disease (COPD) have been shown 
to have higher numbers of IL-22 positive immune cells like Th17 cells (Di Stefano, et al. 
2009). Compared to non-smoking controls, IL-22 levels and IL-22 positive T cell 
populations were significantly higher in the peripheral blood and sputum of smokers and 
patients with COPD (Paats, et al. 2012, Zhang, et al. 2013).  
1.3 IL-22 and cancer 
1.3.1 Relationship between IL-22 and malignancies 
So far, the participation of IL-22 in tumorigenesis paints a complex picture and its effects 
differ not only based on the tissue of origin, but also on the stage of disease (reviewed in: 
Lim and Savan 2014). In hematological malignancies aberrantly expressing the IL-22 
receptor complex, IL-22 can act as an autocrine factor to enhance cancer cell survival 
(Bard, et al. 2008). Overexpression of IL-22-Ra1 has been observed in several types of 
lymphomas (Bard, et al. 2008, Ciccia, et al. 2015, Gelebart, et al. 2011, Ito, et al. 2014). 
However, the exact mechanisms for such aberrant expression remains unclear. 
In cancers of non-hematopoietic origin, IL-22 has been proposed to either play an important 
role within the tumor microenvironment or to act directly on IL-22-Ra1 bearing cells. IL-22 
signaling induces the expression of several genes downstream of STAT3, which mediate 
pro-inflammatory, pro-survival or anti-apoptotic effects (reviewed in: Lim and Savan 2014). 
Genetic studies support these findings, as IL-22 single nucleotide polymorphisms (SNPs) 
were correlated with the risk of developing lung (Liu, et al. 2014), gastric (Qin, et al. 2015), 
and bladder cancer (Zhao, et al. 2015). 
In terms of outcomes, higher expression of IL-22 or IL-22-Ra1 have been shown to 
correlate with progression of disease and lower overall survival in colorectal (Wu, et al. 
2013), gastric (Zhuang, et al. 2012), and pancreatic cancer (Wen, et al. 2014). The 
presence of IL-22 secreting cells is also linked to a more aggressive phenotype in breast 
(Kim, et al. 2014), lung (Kobold, et al. 2013, Zhang, et al. 2008), and skin (Nardinocchi, et 
al. 2015, Zhang, et al. 2013) cancers. Protection from chemotherapy through IL-22 can play 
a role in colorectal (Wu, et al. 2014) and lung (Kobold, et al. 2013) cancer. Interestingly, it 
was also observed that recurrent non-small cell lung cancer (NSCLC) tissue had elevated 
levels of IL-22 and IL-22-Ra1 expression in comparison with the primary tumor (Bi, et al. 
2016). 
1.3.2 Potential mechanisms of IL-22 driven pro-tumoral phenotypes 
IL-22 does not seem to promote oncogenesis or mutagenesis under physiological 
circumstances, but rather accelerates the development of induced or nascent tumors. IL-22 
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overproduction in adipose tissue did not favor spontaneous tumorigenesis in a transgenic 
mouse model with normal diet, but led to liposarcoma after several months when mice were 
fed with a high-fat diet (Wang, et al. 2011). In the liver, overexpression of IL-22 in 
transgenic mice did not cause significantly higher spontaneous tumor incidence, but a 
higher incidence of carcinogen-induced hepatocellular carcinoma (Park, et al. 2011). In 
accordance with these findings, fewer induced liver tumors were observed in IL-22 deficient 
mice (Jiang, et al. 2011).  
IL-22 may also play a role in the transformation or implantation of tumor cells and activate 
epithelial-mesenchymal transition (EMT). For example, IL-22 enhanced the migration of 
A549 lung cancer cells (Ye, et al. 2012) and increased the invasiveness of pancreatic 
cancer cells by inducing matrix metalloproteinases (Wen, et al. 2014). More recently, it has 
been demonstrated that invasiveness of papillary thyroid cancer was caused by IL-22 via 
higher miR-595 expression (Mei, et al. 2016). Closely linked to the metastatic capacity is 
the ability of cancer cells to attract new blood vessels. IL-22 seems to induce angiogenesis 
in a feed-forward paracrine loop through induction of growth factors and chemotaxis of 
endothelial cells (reviewed in: Lim and Savan 2014). For example, pancreatic carcinoma 
cells have been shown to secrete the vascular endothelial growth factor (VEGF) after IL-22 
stimulation (Curd, et al. 2012). Similarly, IL-22 secreted from tumor infiltrating lymphocytes 
in colorectal cancer patients increased expression of VEGF in mice with patient derived 
xenografts (Jiang, et al. 2013). 
In addition to the pro-tumor inflammatory microenvironment with neoangiogenic and 
proliferative properties, IL-22 has been linked to the induction of stemness (Hanash, et al. 
2012). IL-22-KO mice were found to have a significant reduction in expression of stemness 
genes such as SOX2 or NANOG (Khosravi, et al. 2016). For colorectal cancer, IL-22 
induced the expression of stem cell markers via STAT3 activation and promoted sphere 
formation in in vitro surrogate assays for stemness (Kryczek, et al. 2014). Recently, it has 
been shown that IL-22 can also promote stemness in pancreatic ductal adenocarcinoma 
(PDAC) and that worse prognosis of patients with high IL-22-Ra1 expression can be linked 
to higher stemness potential (He, et al. 2018, Lanfranca, et al. 2017).  
Nonetheless, some studies argue that IL-22 hinders tumor progression, for instance via 
STAT1 pathways. In renal cell carcinoma IL-22 decreased growth of tumor cells in vitro and 
in a murine xenograft model through a dose-dependent increase of pSTAT1 (Zhang, et al. 
2011). Similarly, IL-22 inhibited growth of murine breast cancer cells by inducing cell cycle 
arrest (Weber, et al. 2006) and prolonged survival in a model of murine colon cancer 
(Nagakawa, et al. 2004). IL-22 was also shown to inhibit viral and alcohol-induced 
hepatocellular carcinoma (Saalim, et al. 2016). However, anti-growth effects of IL-22 
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appear to work through a distinct non-canonical signaling pathway linked to chronic fibrotic 
diseases (reviewed in: Lim and Savan 2014). It is also important to stress that the number 
of articles arguing in the direction of IL-22 as a tumor-controlling agent are many times 
outnumbered by those showing its pro-tumoral effects. Such considerations tend into the 
direction that the anti-tumoral activity of IL-22 might be very restricted to distinct situations 
or cell systems rather than a general mechanism.  
In summary, the role of IL-22 in tumor development can be described as a double-edged 
sword. Initially, IL-22 diminishes epithelial damage and accelerates repair, thereby reducing 
the duration and extent of inflammatory signals and counteracting tumorigenic signals. 
However, IL-22 can support the transition from pre-existing inflammation to cancers and 
induces the maintenance of established tumors, as best described for the case of colon 
cancer.  
1.3.3 IL-22 blockade as a potential cancer therapy 
The IL-22-IL-22-R axis can be an important novel target in cancer immunology research. 
Several existing therapies already approved by regulatory agencies such as the FDA 
indirectly affect expression of IL-22 in patients. For example, anti-TNFa treatment blocks 
Th22 cell differentiation, thereby transiently decreasing IL-22 production. A new neutralizing 
antibody targeting IL-12p40 (ustekinumab), thereby inhibiting IL-12 and IL-23, has been 
shown to inhibit differentiation of Th1, Th17 and Th22 cells alike (Koutruba, et al. 2010). 
However, global inhibition of TNFa or IL-12 carry the risk of severe side effects, especially 
in cancer types where tumor eradication is dependent upon a functioning immune system. 
STAT3-targeted therapies have been developed, however with disappointing results. Side 
effects were linked to the loss of its homeostatic functions when inhibiting STAT3 globally 
(Furqan, et al. 2013). Clinical trials with anakinra, a soluble IL-1R antagonist, in patients 
with pancreatic and breast cancer are currently being performed, showing promising 
preliminary data (O'Shaughnessy, et al. 2016, Whiteley, et al. 2016). Along the same lines, 
a recent study showed that anti-inflammatory therapy targeting IL-1b significantly reduced 
lung cancer incidence and mortality (Ridker, et al. 2017). 
1.3.4 IL-22-producing immune cells in cancer 
For several types of cancer increased levels of IL-22-producing immune cells have been 
observed in both the tumor and the blood. So far, the intratumoral presence of IL-22-
producing cells has been shown mainly in gastric, colonic, hepatocellular, pancreatic, and 
lung carcinomas (Jiang, et al. 2011, Jiang, et al. 2013, Kobold, et al. 2013, Zhuang, et al. 
2012).  
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In human lung carcinomas, IL-22+NCR+ ILC3 cells were found in NSCLC tissue, with 
significantly higher frequencies in stages I or II compared to more advanced stages 
(Carrega, et al. 2015). IL-22 was also higher in malignant pleural effusions than in patients 
with tuberculous effusions (Zhang, et al. 2008), and elevated Th1, Th17 and Th22 cell 
counts have been observed in such malignant pleural effusions (Ye, et al. 2012). 
In the case of colorectal cancer patients, levels of both IL-17 and IL-22 correlated positively 
with tumor staging (Petanidis, et al. 2013) and dysplastic regions displayed higher 
concentrations of intratumoral IL-22+ ILCs (Kirchberger, et al. 2013). It has been suggested 
that Th22 cells which accumulate in colorectal cancers are associated with the chemotactic 
effect of the tumor microenvironment and amplified tumor growth via STAT3 activation 
(Huang, et al. 2015). CD3+CD4+CD8- memory but not naïve T cells were identified as major 
producers in colon cancer, with 30 % co-secreting IL-17 and less than 5 % IFNg (Kryczek, 
et al. 2014).  
Increased counts of IL-22+CD4+ T cells were found in gastric tumors compared to 
peritumoral tissue and non-tumor tissue (Zhuang, et al. 2012). Compared to healthy 
controls, gastric cancer patients also had increased counts of IL-17- and IL-22-producing T 
cells in the blood (Liu, et al. 2012). In pancreatic cancer, intratumoral frequency of both IL-
22+CD4+ T cells and IL-22 levels were higher than in the peripheral blood of both patients 
and healthy donors (Xu, et al. 2014). For pancreatic ductal adenocarcinoma (PDAC), FACS 
analysis was recently used to identify ILC3 and Th22 cells as the main source of IL-22 in 
both human and murine specimens (Lanfranca, et al. 2017). Tumor-infiltrating lymphocytes 
in hepatocellular carcinoma also exhibited a higher IL-22+ cell fraction and increased serum 
levels of IL-22 represent a negative prognostic markers in virus-associated hepatocellular 
carcinoma (Waidmann, et al. 2014). 
A growing body of data exists as to which cells produce IL-22 in the cancer environment 
and what clinical consequences their presence might have. However, it is still very unclear 
if and how cancer cells regulate IL-22 production. A greater understanding thereof would 
have direct consequences for designing therapeutic interventions targeting the pathway.  
1.4 Research objectives 
IL-22 has been described as a tumor promoting cytokine. Aberrant activation of the IL-22-
IL-22-R axis has been associated with different cancer entities including breast and lung, 
but also colon, gastric and pancreatic cancers. The main cellular sources of IL-22 are 
thought to be T cells and innate lymphoid cells. However, neither the exact mechanism of 
induction nor the exact cellular sources have been characterized for lung and breast 
cancers. A previous doctoral student in the laboratory (Dr. Cornelia Voigt) showed that 
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cancer cells can directly induce IL-22 production from murine and human immune cells. 
Her research further indicated that this process is driven by IL-1a in murine and IL-1b in 
human immune cells. She could show that these cytokines primarily acted on CD3+ T cells 
and mediated IL-22 production via the transcription factors AhR and RORgt. Based on 
these previous observations, the objective of this thesis is to further elucidate the following:  
• to identify IL-22-producing T cell subtypes in murine and human breast and lung 
cancer models 
• to characterize the factors and expose the exact mechanism by which IL-22 
production is induced in these T cell subtypes 
• to characterize IL-22-producing tumor infiltrating lymphocytes in human breast 
cancer tissue. 
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2 Materials 
2.1 Technical equipment 
Analytical balance CPA1003S Sartorius Laboratory, Göttingen, DE 
Autoclave Varioklav 500E HP Medizintechnik, München, DE 
Cell culture incubator BBD 6220 Heraeus, Hanau, DE 
Centrifuges 3L-R Multifuge Heraeus, Hanau, DE 
 Centrifuge 5318R Eppendorf, Hamburg, DE 
 Rotina 420R Hettich GmbH, Tuttlingen, DE 
FACS Canto II BD Biosciences, Franklin Lakes, USA 
Heating block Thermomixer 5436 Eppendorf, Hamburg, DE 
Laminar flow hoods HeraSAFE KS Heraeus, Hanau, DE 
MACS separators QuadroMACS Miltenyi Biotec, Bergisch Gladbach, DE 
Microscope Axiovert 40C Zeiss, Jena, DE 
 Axiovert HAL 100 Zeiss, Jena, DE 
Multilabel plate reader Mithras LB 940 Berthold, Bad Wildbad, DE 
Photometer NanoDrop 2000c Thermo Fisher, Waltham, USA  
pH-Meter inoLab pH 720 WTW GmbH, Weilheim, DE 
Vortex mixer RS-VA 10 Phoenix, Garbsen, DE 
Water bath Unitherm-HB uni equip, München, DE 
2.2 Materials 
Cell culture flasks (T25 to T175) Costar Corning, New York, USA 
Cell culture plates (6- to 96-well) BD Medical, Franklin Lakes, USA 
Cryotubes  greiner bio-one, Frickenhausen, DE 
Disposable scalpels (No. 10) FEATHER, Osaka, JP 
ELISA microplates (96-well) Costar Corning, New York, USA 
Eppendorf tubes (0.5 ml; 1.5 ml; 2.0 ml) Sarstedt, Nürnbrecht, DE 
FACS tubes  BD Biosciences, Franklin Lakes, USA 
Nylon filter SmartStrainers (100 µm, 30 µm) Miltenyi Biotec, Bergisch Gladbach, DE 
Petri dishes  BD Medical, Franklin Lakes, USA 
Pipetboy  Hirschmann Laborgeräte, Eberstadt, DE 
Pipettes  Eppendorf, Hamburg, DE 
Polypropylene round bottom tubes BD Biosciences, Franklin Lakes, USA  
Serological pipettes  Costar Corning, New York, USA 
Syringes with Luer-Lok-Tip (50 ml) BD Medical, Franklin Lakes, USA 
Syringes (2 ml, 10 ml)  BD Medical, Franklin Lakes, USA 
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2.3 Chemicals and reagents 
Albumin Fraction V (BSA) Sigma-Aldrich, St. Louis, USA 
BD Pharm Lyse™ Lysing Buffer (10x) BD Biosciences, Franklin Lakes, USA 
Biocoll Separating Solution (d = 1,077 g/ml) Biochrom Merck Millipore, Darmstadt, DE 
Brefeldin A  Sigma-Aldrich, St. Louis, USA 
Collagenase D  Sigma-Aldrich, St. Louis, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, USA 
DNase I  Roche, Mannheim, DE 
Ethanol 96-100 %  Sigma-Aldrich, St. Louis, USA 
FACSFlow  BD Biosciences, Franklin Lakes, USA 
Heparin-Sodium (25,000 I.U./ 5 ml) Ratiopharm, Ulm, DE 
Ionomycin calcium salt   Sigma-Aldrich, St. Louis, USA 
Isoflurane  CP Pharma, Burgdorf, DE 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich, St. Louis, USA 
Sulfuric acid (2 N)  Pharmacy of LMU, München, DE 
Trypan blue  Sigma-Aldrich, St. Louis, USA 
Tween-20  Roth, Karlsruhe, DE 
2.4 Assays 
Bio-Plex Cell Lysis Kit  Bio-Rad, San Diego, USA 
CountBright™ Absolute Counting Beads Invitrogen, Carlsbad, USA 
Cytofix/Cytoperm  BD Biosciences, Franklin Lakes, USA 
DC™ Protein Assay  Bio-Rad, San Diego, USA 
IC Fixation/Permeabilzation Kit eBioscience, San Diego, USA 
IL-22 ELISA (human)  R&D Systems, Minneapolis, USA 
IL-22 ELISA (murine)  Antigenix America, Huntington State, USA 
MACS Pan T cell isolation kit, human Miltenyi Biotec, Bergisch Gladbach, DE 
MACS Pan T cell isolation kit II, mouse Miltenyi Biotec, Bergisch Gladbach, DE 
MACS naive CD4+ T cell isolation kit, mouse Miltenyi Biotec, Bergisch Gladbach, DE 
MACS naive CD4+ T cell isolation kit II, human Miltenyi Biotec, Bergisch Gladbach, DE 
Zombie NIR Fixable Viability kit BioLegend, San Diego, USA 
2.5 Cytokines and antagonists 
CRID3 sodium salt  Tocris Bioscience, Bristol, UK 
InVivoMAb anti-mouse IL-1R (clone: JAMA-147) BioXCell, West Lebanon, USA 
InVivoMAb polyclonal Armenian hamster IgG BioXCell, West Lebanon, USA 
Kineret® (anakinra) (100 mg/0.67 ml) Sobi, Stockholm, SE 
Recombinant IL-1a (human) PeproTech, Rocky Hill, USA 
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Recombinant IL-1a (murine) BioLegend, San Diego, USA 
Recombinant IL-1b (human) PeproTech, Rocky Hill, USA 
Recombinant IL-23 (murine) BioLegend, San Diego, USA 
2.6 Antibodies 
Table 2: FACS antibodies 
Antibody Reactivity Clone Manufacturer 
Anti-CD3e-APC Human OKT3 BioLegend 
Anti-CD4-FITC Human A161A1 BioLegend 
Anti-CD8-APC-Cy7 Human HIT8a BioLegend 
Anti-CD11b-APC Human ICRF44 BioLegend 
Anti-IFNg-PE-Cy7 Human 4S.B3 BioLegend 
Anti-IL-17-FITC Human BL168 BioLegend 
Anti-IL-22-PE Human 22URTI eBioscience 
Anti-CD3e-APC Murine 145-2C11 BioLegend 
Anti-CD4-PaqBlue Murine GK1.5 BioLegend 
Anti-CD8-APC-Cy7 Murine 53-6.1 BioLegend 
Anti-IL-22-PE Murine 140301 R&D 
Anti-CD45-PerCp5.5 Murine 30-F11 BioLegend 
TruStain FcX  Human - BioLegend 
TruStain FcX (anti-CD16/32) Murine 93 BioLegend 
Mouse IgG1k-PE isotype control - 
 
MOPC-21 BioLegend 
Rat IgG2A-PE isotype control - 54447 R&D 
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2.7 Cell lines, supplements and media 
2.7.1 Cell lines 
Table 3: Cell lines  
Cell line Species Description Medium Reference 
4T1 Murine Breast cancer (BALB/c) DMEM+++ (Dexter, et al. 1978) 
A549 Human Lung adenocarcinoma DMEM+++ ATCC: CCL185 
 CAMA1 Human Breast cancer DMEM+++ ATCC: HTB-21 
E0771 Murine Breast cancer 
(C57BL/6) 
RPMI+++ CH3 BioSystems, USA 
H1339 Human Small cell lung cancer RPMI+++ ATCC: CRL-5979 
HCC827 Human Lung adenocarcinoma RPMI+++ ATCC: CRL-2868 
MCF-7 Human Breast cancer DMEM+++ ATCC: HTB-22 
MD-AMB-231 Human Breast cancer  DMEM+++ ATCC: HTB-26 
* all human cell lines were identified through STR profiling 
 
2.7.2 Supplements 
Dulbecco’s modified Eagle’s medium (DMEM) PAA Laboratories, Pasching, AT 
Fetal bovine serum (FBS) – heat inactivated Gibco, Carlsbad, USA 
Human serum  Sigma-Aldrich, St. Louis, USA 
L-Glutamine (200 mM)  PAA Laboratories, Pasching, AT 
Non-essential amino acids (NEAA) Gibco, Carlsbad, USA 
Penicillin/Streptomycin (100x) PAA Laboratories, Pasching, AT 
Phosphate-buffered Saline (PBS) PAA Laboratories, Pasching, AT 
Roswell Park Memory Institute (RPMI) 1640 PAA Laboratories, Pasching, AT 
Sodium pyruvate (100 mM) PAA Laboratories, Pasching, AT 
VLE-RPMI 1640  Biochrom, Berlin, DE 
2.7.3 Media
Complete DMEM medium (DMEM+++) 
DMEM full medium  500 ml 
FBS    50 ml 
Penicillin   1 IU/ml 
Streptomycin   100 µg/ml 
L-Glutamine   2 mM 
 
 
 
Complete RPMI medium (RPMI+++) 
RPMI 1640 full medium 500 ml 
FBS    50 ml 
Penicillin   1 IU/ml 
Streptomycin   100 µg/ml 
L-Glutamine   2 mM 
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PBMC medium 
VLE-RPMI 1640  500 ml 
Human serum   50 ml 
Penicillin   1 IU/ml 
Streptomycin   100 µg/ml 
L-Glutamine   2 mM 
Sodium pyruvate  1 mM 
NEAA (100 %)   1 % 
 
Cryopreservation medium 
FBS    400 µl 
DMSO    100 µl 
Medium with cells  500 µl 
Digestion medium 
RPMI 1640   1 ml 
Collagenase D   1 mg/ml 
DNase I   0.05 mg/ml 
 
FACS buffer 
PBS    500 ml 
FBS    10 ml 
 
 
 
2.8 Software 
Adobe Creative Suite CS6 Adobe Systems, San Jose, USA 
BD FACSDiva  BD Biosciences, Franklin Lakes, USA 
EndNote X7  Thomson Reuters, Carlsbad, USA 
FlowJo 8.7  Tree Star, Ashland, USA 
GraphPad Prism Version 5.0 GraphPad Software, La Jolla, USA 
Microsoft Office 2016  Microsoft, Redmond, USA 
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3 Methods 
3.1 Cell biological methods 
3.1.1 General cell culture conditions 
All cell lines were cultured in cell culture flasks in incubators at 37 °C, 5 % CO2 and 95 % 
humidity. Cell manipulations were performed under sterile cell culture conditions under a 
laminar flow hood. Adherent cells were detached by incubating the cells with a Trypsin 
solution for 5 minutes at 37 °C or by using sterile cell scrapers. Detached cells were spun 
down at 400 g for 5 min and resuspended in full growth medium. Cells were supplemented 
with new medium three times per week and divided at 80 % confluence. Neubauer 
hemocytometers were used to determine number and viability of Trypan blue stained cells. 
3.1.2 Generation of cell-free tumor supernatants 
Tumor cells were trypsinized, centrifuged and counted. 0.5 x 106 cells per ml were plated in 
2 ml fresh medium in 6 wells and kept in the incubator for four to six days. Tumor cell-free 
supernatants were collected by centrifuging twice at 400 g for 5 min at 4 °C in canonical 50 
ml Falcon tubes. 
3.1.3 Isolation of splenocytes 
WT BALB/c mice were killed by cervical dislocation and spleens were taken into 1.5 ml 
tubes containing complete RPMI medium. Attached fat tissue was removed and a single 
cell suspension was generated by mashing the organs through a 100 µm strainer attached 
to a 50 ml conical tube under sterile conditions, using the plunger end of a syringe. Cells 
were washed through the strainer with full medium and filtered through an additional 30 µm 
strainer. Cells were centrifuged at 400 g for 5 minutes at 20 °C. Red blood cell lysis was 
performed using 2 ml of BD Pharm Lyse™ buffer according to the manufacturer’s protocol. 
After 2 min, 10 m of complete RPMI medium was added to stop the lysis. Cells were 
centrifuged and washed with full medium. Finally, the splenocytes were counted using 
Neubauer hemocytometers and used for stimulation assays. 
To examine specific subpopulations, MACS enrichment was used according to the 
manufacturer’s protocol. MACS purities were measured with flow cytometry using the 
appropriate FACS antibodies as described in section 3.2.2.  
3.1.4 Isolation of cells from lung tissue 
Lungs were removed from sacrificed mice and placed into 1.5 ml tubes containing complete 
RPMI medium. The lungs were homogenized with scalpels and incubated in digestion 
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medium at 37 °C for 30 min on a shaking heating block. Next, single cell suspensions were 
generated as described in section 3.1.2. 
3.1.5 Isolation of PBMCs 
Peripheral blood mononuclear cells (PBMCs) were isolated using a density gradient with 
Biocoll (d = 1,077 g/ml). 30 – 50 ml of blood was drawn from donors using 50 ml syringes 
covered with 5,000 I.U. Heparin-Sodium. The blood was diluted 1:1 with PBS. 20 ml of the 
diluted blood was carefully layered over 10 ml Biocoll in a 50 ml Falcon conical tube and 
centrifuged at 1,000 g at 20 °C in a swinging-bucket rotor without brake. Next, the 
interphase ring containing PBMCs was carefully aspirated, transferred to a new 50 ml tube 
and resuspended in 50 ml PBS. After centrifugation (10 min, 500 g, 20 °C), all PBMC 
pellets of one donor were collected and washed once more with PBS (10 min, 400 g, 4 °C) 
before being resuspended in PBMC growth medium containing VLE RPMI and used in 
stimulation assays. 
3.1.6 Preparation of breast cancer tissue  
Tumor tissue was homogenized with scalpels and incubated in digestion medium at 37 °C 
for 30 min on a shaking heating block. Subsequently, the cell suspensions were passed 
through a 100 µm and then a 30 µm cell strainer. To remove erythrocytes, cell suspensions 
were resuspended in 2 ml of BD Pharm Lyse™ buffer and incubated for 2 min at 20 °C.  
Erythrocytes were removed through incubation with BD Pharm Lyse™ buffer for 2 min. 
Cells were washed once and counted using hemocytometers. To assess the cytokine 
expression by tumor infiltrating lymphocytes, isolated single cell suspensions were 
stimulated at 37 °C for 4 h in RPMI 1640 medium containing 50 ng/ml PMA, 1 µg/ml 
ionomycin and 2.5 µg/ml brefeldin A (Golgi stop) at a concentration of 2 x 106 cells per ml.  
3.1.7 Cell lysates 
Approximately 1.5 mm2 big pieces of primary tumor tissues were snap-frozen in liquid 
nitrogen. After homogenization, the tissues were lysed using the Bio-Plex cell lysis kit 
according to the manufacturer’s protocol. Cell debris was removed by centrifugation at 
10,000 g for 10 min. Protein concentrations of lysates were determined by the Bradford 
method (Detergent Compatible Protein Assay, Bio-Rad), using a microplate reader 
(Berthold Mithras LB940 multilabel plate reader) to detect absorbance at 750 nm. 
3.1.8 Stimulation of cells 
Counted cells were plated in 6- to 96-well plates at a concentration of 2 x 106 cells per ml. 
Recombinant cytokines or antagonists were added in their respective concentrations. 
Stimulation with tumor cell derived supernatants was achieved by replacing 50 % of the 
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medium with the cell-free tumor supernatant. Supernatants were harvested after four to six 
days, centrifuged and frozen at -20 °C for further analysis. 
3.2 Immunological methods 
3.2.1 Enzyme-linked immunosorbent assay 
Several human and murine ELISA kits were used to measure cytokine concentrations in 
cell supernatants and cell lysates. Before analysis, samples were stored at -20 °C to -80 
°C. ELISA and buffer preparation were performed according to the manufacturer’s protocol. 
Absorbance at 450 nm was measured using a microplate reader (Berthold Mithras LB940 
multilabel plate reader). Background correction was at 595 nm. A four parameter logistic 
(4PL) regression was used to calculate protein concentrations from the standard curve.  
3.2.2 Flow cytometry (FACS) 
Flow cytometry allows the quantification of cells according to size, granularity and 
expression of proteins based on fluorophore-conjugated antibodies. For FACS analysis, 
single cell suspensions were isolated as described in section 3.1.  
After stimulation as described in section 3.1.5, cells were washed with FACS buffer and 
counted. 106 – 107 cells per well were plated in 96-U-well plates. To avoid unspecific 
binding of the antibodies, cells were incubated for 15 min at 4 °C with Fc-block reagent 
added at 1:100 dilution. Cell suspensions were then incubated with fluorochrome-
conjugated antibodies for extracellular targets and Zombie NIR Fixable Viability Dye 
(BioLegend) for live/dead staining for 30 min at 4 °C in the dark. After two washing steps 
with FACS buffer, cells were fixed and permeabilized using the IC Fixation/Permeabilization 
(eBioscience) kit according to the manufacturer’s protocol. Fc-block was added for 15 min 
at 20 °C in the dark. Cells were then stained in the permeabilization buffer for 30 min at 20 
°C with antibodies directed against intracellular antigens. CD4 staining was repeated due to 
receptor internalization as a result of the stimulation mix. Finally, cells were centrifuged at 
400 g for 5 min at 20 °C and washed twice with 200 µl permeabilization buffer and once 
with 200 µl FACS buffer. After centrifugation, cell pellets were resuspended in FACS buffer 
and analyzed by the FACS Canto II (BD Biosciences) run on FACSDiva software. For 
quantifying cell populations, CountBright™ beads were added to the samples prior to FACS 
analysis following the manufacturer’s recommendations. Absolute counts were calculated 
according to the formula: (number of positive cells/number of bead events) ´ number of 
beads added. Data analysis was performed using FlowJo 8.8.2. 
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3.3 Animal experiments 
3.3.1 Care of laboratory animals 
Six to eight weeks old wild type (WT) female mice on BALB/c and C57/BL6 background 
were used for in vivo experiments. Mice were obtained from Janvier (Saint-Berthevin 
Cednex, France) and Charles River (Sulzfeld, Germany). The animals were held in the 
animal facility “Tierhaltung der Medizinischen Klinik Innenstadt” at least one week before 
the start of experiments. All animal experiments have been approved by the local authority, 
Regierung von Oberbayern (reference number: 55.2.1.54-2532-90/12) and adhered to the 
NIH guidelines for the care and use of laboratory animals. 
3.3.2 Subcutaneous tumor models  
For subcutaneous tumor models, 1.25 x 105 4T1 or 2 x 105 E0771 murine breast cancer 
cells were resuspended in 100 µl PBS and injected into the subcutaneous tissue of the right 
flank of young female mice. Tumor size was measured three times per week using an 
electronic caliper. It was defined as area in mm2 (length in mm x width in mm). Daily 
scoring included tumor size and morphology, body weight, behavior and general condition.  
When termination criteria were reached, mice were anesthetized with isoflurane inhalation 
and sacrificed via cervical dislocation. Organs were removed using forceps and scissors 
and kept in RPMI on ice until further processing. 
3.4 Primary breast cancer patients 
Breast cancer patients were recruited from the department of gynecology and obstetrics at 
the Klinikum Dritter Orden, Munich. Tissue samples were collected from eleven female 
patients. All patients had a confirmed diagnosis of mammary carcinoma and four of these 
were classified as triple negative breast cancer. No patient had received previous treatment 
in the form of (radio-)chemotherapy. Ethical approval was obtained from the Ludwig-
Maximilians-Universität Ethics Committee (reference number 249-15). Written informed 
consent was obtained from all patients prior to collection of specimens. Patient recruitment 
was done in line with respective institutional policies and in accordance with the Declaration 
of Helsinki. Tumor specimens were only obtained from patients undergoing clinically 
indicated surgery. Seven patient samples were large enough to provide sufficient material 
for FACS analysis (see section 3.1.5 and 3.2.2). From all eleven patients, a small piece 
was snap-frozen in liquid nitrogen in order to measure protein concentrations with ELISA 
(see section 3.2.1) from cell lysates (see section 3.1.7). 
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Table 4: Cell lines  
Characteristic No. of patients 
  
Union for International Cancer control stage  
    0 0 
    I 5 
    IIA 1 
    IIB 2 
    IIIA 0 
    IIIB 0 
    IIIC 0 
    IV 3 
Histology  
    No specific type 11 
       Triple-negative breast cancer 4 
Previous treatment  
    Chemotherapy 0 
    Radio-Chemotherapy 0 
Age (y)  
    50-59 4 
    60-69 1 
    70-79 3 
    80-89 3 
Gender  
    Female  11 
    Male 0 
3.5 Statistical analysis 
Statistics were calculated using GraphPad Prism software 5.0. Unless stated otherwise, 
arithmetic mean and standard error of the mean were calculated. Statistical significance 
was determined using the two-sided Student’s t-test for unpaired samples or for paired 
samples when results from the same individual human donor were compared. Mann-
Whitney U test was used for significance testing comparing data points from individual 
mice. Tumor growth curves were analyzed by two-way ANOVA, with correction for multiple 
testing by the Bonferroni method.  
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4 Results 
4.1 In vitro characterization of IL-22-producing cells in murine model 
4.1.1 Purified CD4+ T cells but not CD4-depleted splenocytes produce IL-22 
Previous data from our group has shown that CD3+ T cells are the major source of IL-22 
production by splenocytes when stimulated with cell-free tumor supernatant from murine 
4T1 cells (Voigt, et al. 2017). Using MACS purification, it was demonstrated that IL-22 was 
conserved in the CD3+ fraction while being significantly reduced in CD3-depleted fraction.  
To further analyze the subgroup of IL-22-producing T cells, CD4+ cells were purified and 
stimulated. Purity of the CD4+ T cell fraction was between 82 and 99 %, while the CD4-
depleted splenocytes contained less than 5 % CD4+ cells (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Murine IL-22 production in CD4+ T cells and CD4- splenocytes after stimulation 
with tumor cell supernatant.  
Stimulation of total splenocytes, MACS-enriched CD4+ T cells and CD4- splenocytes (2 x 106 
per ml) for six days with cell-free supernatant from 4T1 cell culture. IL-22 concentration was 
quantified by ELISA. Values of four independent experiments are shown, with n = 8 different 
donors. Error bars represent SEM and statistical significance was calculated using two-sided 
Student’s t-tests. 
 
MACS-enriched CD4+ T cells produced IL-22 in similar amounts to unselected splenocytes 
upon stimulation with tumor-cell supernatant. In contrast, IL-22 secretion was significantly 
lower, though still detectable, in the CD4-depleted fraction. Consequently, CD4+ T cells can 
be identified as the responsible CD3+ T cell subgroup producing IL-22 after stimulation with 
4T1 tumor supernatant. 
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Our group could also previously show that the IL-22 induction by 4T1 tumor cell 
supernatant was dependent upon IL-1a and IL-23 (Voigt, et al. 2017). To demonstrate that 
this effect was also relevant for and mediated through CD4+ T cells, stimulation of CD4+ 
and CD4- splenocytes was repeated with IL-1a and IL-23. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Murine IL-22 production in CD4+ T cells and CD4- splenocytes after 
stimulation with recombinant proteins.  
Stimulation of total splenocytes, MACS-enriched CD4+ T cells and CD4- splenocytes (2 x 106 
per ml) for six days with cell-free supernatant from (A) 100 ng/ml recombinant IL-1a or (B) 
100 ng/ml recombinant IL-1a and IL-23. IL-22 concentration was quantified by ELISA. Values 
of a minimum of four independent experiments are shown, with n = 4 (A) and n = 7 (B) 
different donors. Error bars represent SEM and statistical significance was calculated using 
two-sided Student’s t-tests. 
 
IL-22 production was at comparable levels in CD4+ T cells and mixed splenocytes after 
stimulation with recombinant IL-1a, but significantly reduced in the CD4-depleted fraction. 
The effect was slightly more pronounced when recombinant IL-23 was added. CD4+ T cells 
are thus the main producers of IL-22 after stimulation with 4T1 tumor supernatant or 
recombinant IL-1a and IL-23. 
4.1.2 Mixed CD4+ T helper cell population produce IL-22 
To further characterize the source of IL-22 within the population of CD4+ T cells, MACS-
enriched CD4+ T cells were analyzed by flow cytometry after stimulation with 4T1 tumor cell 
supernatant or recombinant IL-1a.  
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Figure 5: FACS analysis of murine T helper cell subgroup after stimulation with tumor 
cell supernatant or recombinant IL-1a.  
MACS-enriched CD4+ T cells (106 per well) were cultured in 96-well plates and stimulated 
with (A) 4T1 cell-free tumor supernatant or (B) 20 ng/ml recombinant IL-1a for 4 days. They 
were then restimulated using PMA and ionomycin in the presence of brefeldin A and stained 
intracellularly for IL-22. Subsequently, they were analyzed via flow cytometry for IL-22 
expression in Th1 (CD3+CD4+IFNg+), Th17 (CD3+CD4+IL-17+), and Th22 (CD3+CD4+IL-17-
IFNg-) cells. Values of a minimum of three independent experiments are shown, with n = 6 (A) 
and n = 5 (B) different donors. Error bars represent SEM and statistical significance was 
calculated using two-sided Student’s t-tests. 
 
Stimulation with either 4T1 tumor supernatant or recombinant IL-1a resulted in an 
upregulation of IL-22. As expected, the majority of IL-22+ cells were CD3+CD4+. They 
consisted of a mixed Th1, Th17 and Th22 population, with Th22 cells representing the most 
prominent subpopulation. Results were similar for stimulation with either 4T1 cell-free tumor 
supernatant or recombinant IL-1a. 
4.1.3 CD4+CD44+ memory T cells as main source of IL-22 
Mechanistically, IL-1a can either lead to differentiation of naïve T cells into IL-22-producing 
subsets, or directly induce IL-22 production from an existing pool of Th1, Th17, and Th22 
cells. In order to differentiate whether naïve or memory T cells were the source of IL-22 in 
this model, splenocytes were sorted using MACS. Mouse naïve CD4+ T cells were isolated 
by depletion of CD44+ memory T cells and non-CD4+ T cells. Purity of the CD4+ T cell 
fraction was between 84 and 98 %. The naïve CD4- splenocyte fraction contained less than 
22 % CD4+ cells and less than 1 % CD4+CD44+ memory T cells (data not shown). 
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Figure 6: Murine IL-22 production in naïve CD4+ T cells and CD4+CD44+ memory T cells. 
Stimulation of total splenocytes, MACS-enriched naïve CD4+ T cells, and CD4+CD44+ memory 
T cells with CD4- splenocytes (2 x 106 per ml) for six days with cell-free supernatant from 4T1 
cell culture. IL-22 concentration was quantified by ELISA. Values of three independent 
experiments are shown, with n = 8 different supernatants. Error bars represent SEM and 
statistical significance was calculated using two-sided Student’s t-tests. 
 
Naïve CD4+ cells showed no relevant IL-22 production after stimulation with recombinant 
IL-1a. In contrast, CD4+CD44+ memory T cells with CD4-depleted splenocytes produced IL-
22 levels similar to that of the mixed splenocyte population. Given that CD4- splenocytes on 
their own were shown to induce only low levels of IL-22 (see Figure 3), these findings 
suggest that IL-1 containing tumor supernatant does not lead to differentiation of naïve T 
cells into IL-22-producing subsets. Instead, pre-existing memory T cells are the target 
population for IL-1-induced IL-22 production in mice. 
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4.2 Effects of blocking IL-1 in vivo 
4.2.1 Blocking of IL-1 reduces tumor progression and production of IL-22 cells 
To confirm the in vitro findings of IL-1 induced IL-22 production by CD4+ cells through 
cancer cells, the impact of IL-1 blockade on IL-22 production and tumor growth was tested 
in vivo. First, 4T1 tumor-bearing mice were treated every second day with a neutralizing IL-
1R antibody.  
 
Figure 7: Neutralizing IL-1R antibody reduces tumor growth and IL-22 production in 
4T1 breast cancer model. 
1.25 x 105 4T1 tumor cells were injected in the right flank of BALB/c mice (n = 10 mice per 
group). Beginning on day 0, mice were treated with 300 µg InVivoMAb anti-mouse IL-1R 
antibody (clone: JAMA-147) or isotype control (InVivoMAb polyclonal Armenian hamster IgG) 
i. p. every second day. (A) shows tumor growth curves, error bars representing SEM and 
statistical significance was calculated by two-way ANOVA with correction for multiple testing. 
(B) shows absolute number of IL-22+CD45+ cells in the lung as determined by FACS analysis. 
Error bars represent SEM and statistical significance was calculated by Mann-Whitney U test. 
 
Tumor growth was significantly reduced in the IL-1R antibody-treated group compared to 
the isotype control. As suggested by the in vitro findings, IL-22 production, as measured by 
the number of IL-22+ cells in the lung, was also reduced.  
Similarly, mice bearing the E0771 breast cancer model were treated with anakinra, a 
soluble IL-1R antagonist. Similar to the results in the 4T1 model, tumor growth was 
decreased, and IL-22 production was reduced through inhibition of IL-1 activity. 
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Figure 8: Soluble IL-R antagonist anakinra reduces tumor growth and IL-22 production 
in E0771 breast cancer model.   
2.5 x 105 E0771 tumor cells were injected in the right flank of C57BL/6 mice (n = 15 mice per 
group). Beginning on day 0, mice were treated with 1 mg anakinra or PBS i. p. every day. (A) 
shows tumor growth curves, error bars representing SEM and statistical significance was 
calculated by two-way ANOVA with correction for multiple testing. (B) shows absolute number 
of IL-22+CD45+ cells in the lung as determined by FACS analysis. Error bars represent SEM 
and statistical significance was calculated by Mann-Whitney U test. 
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4.3 In vitro characterization of IL-22-producing cells in humans  
4.3.1 Purified CD4+ T cells but not CD4-depleted PBMCs produce IL-22 
The next step was to evaluate whether the findings seen in mice can be translated into the 
human setting. Our group could previously show that human cancer cells induce IL-22 
production from human PBMCs via IL-1b. Mirroring the approach with murine splenocytes, 
PBMCs from human donors were isolated and CD4+ cells were purified. In total, 
supernatants from three human lung cancer cell lines (H1339, A549, and HCC827) and 
three human breast cancer cell lines (MD-AMB-231, CAMA1, and MCF-7) were tested. 
Cells were stimulated first with supernatants from human lung cancer cell lines. In the 
following three figures, purity of the CD4+ T cell fraction was between 92 and 98 %, while 
the CD4- PBMC fraction contained less than 31 % CD4+ cells (data not shown). 
 
Figure 9: Human IL-22 production in CD4+ T cells and CD4- PBMCs after stimulation 
with human lung cancer cell lines.  
Stimulation of total PBMCs, MACS-enriched CD4+ T cells or CD4- PBMCs (2 x 106 per ml) for 
six days with cell-free supernatant from (A) H1339 or (B) A549 cell culture. IL-22 
concentration was quantified by ELISA. Values of a minimum of five independent 
experiments are shown, with n = 14 (A) and n = 14 (B) different donors. Error bars represent 
SEM and statistical significance was calculated using two-sided Student’s t-tests. 
 
When stimulated with supernatants from H1339 or A549 lung cancer cell lines, production 
of IL-22 by CD4+ T cells was higher compared to that from whole PBMCs, while being 
almost absent in the CD4-depleted fraction. 
The same experiments were repeated with supernatants from human breast cancer cell 
lines.  
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Figure 10: Human IL-22 production in CD4+ T cells and CD4- PBMCs after stimulation 
with human breast cancer cell lines.  
Stimulation of total PBMCs, MACS-enriched CD4+ T cells or CD4- PBMCs (2 x 106 per ml) for 
six days with cell-free supernatant from (A) MDA-MB-231 or (B) CAMA1 cell culture. IL-22 
concentration was quantified by ELISA. Values of a minimum of five independent 
experiments are shown, with n = 13 (A) and n = 9 (B) different donors. Error bars represent 
SEM and statistical significance was calculated using two-sided Student’s t-tests. 
 
Previous data from our group indicated that IL-1 family members induce IL-22 from 
PBMCs. To transfer these findings to the identified subpopulation of CD4+ T cells, MACS 
enriched, MACS-enriched CD4+ T cells were subsequently stimulated by recombinant 
proteins.  
 
Figure 11: Human IL-22 production in CD4+ T cells and CD4- PBMCs after stimulation with 
recombinant IL-1a and/or IL-1b. 
Stimulation of total PBMCs, MACS-enriched CD4+ T cells or CD4- PBMCs (2 x 106 per ml) for 
six days with 10 ng/ml recombinant IL-1a and/or IL-1b. IL-22 concentration was quantified by 
ELISA. Values of four independent experiments are shown, with n = 8 different donors. Error 
bars represent SEM and statistical significance was calculated using two-sided Student’s t-
tests. 
Stimulation of human CD4+ T cells with recombinant IL-1a or IL-1b led to significant IL-22 
production, but IL-1b was shown to be a stronger inductor in the human setting. Combining 
both IL-1a and IL-1b also caused IL-22 induction in CD4+ PBMCs, though this was not 
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increased compared to either cytokine alone. As seen in the stimulation with tumor 
supernatants, CD4-depleted PBMCs did not respond to either cytokines. This indicates that 
the CD4+ T cell fraction is the target of IL-1 and the source of IL-22 production within the 
proposed mechanism.  
4.3.2 NLRP3 inflammasome plays an important role in IL-1-induced IL-22 
production 
Production of IL-1b is predominantly regulated by cytosolic molecular complexes, called 
inflammasomes. Nod-like receptor protein 3 (NLRP3) inflammasome activity has been 
described as responsible for IL-1 activation in tumor cells (Dostert, et al. 2008). To identify 
whether this mechanism also applies to the IL-1 induced IL-22 secretion described above, 
the specific NLRP3 inhibitor CRID3 was used to antagonize IL-22 induction in PBMCs 
through cell-free supernatant from human breast cancer cell lines. 
 
Figure 12: IL-22 induction by human breast cancer cell lines can be dose-dependently 
antagonized through NLRP3 inhibition.  
Stimulation of PBMCs for six days with 50 % cell-free supernatant from (A) H1339 or (B) 
MDA-MB-231 in the presence of 0.5, 5 and 50 µM (A) or 50 µM (B) CRID3. DMSO served as 
a negative control. IL-22 concentration was quantified by ELISA. Values of a minimum of five 
independent experiments are shown, with n = 9 (A) and n = 10 (B) different donors. Error 
bars represent SEM and statistical significance was calculated using two-sided Student’s t-
tests. 
 
Addition of CRID3 reduced IL-22 secretion in a dose-dependent manner and consistently 
across different human breast cancer entities. Similar results could be attained by using the 
pan-caspase inhibitor Z-VAD (data not shown). This points towards the contribution of 
inflammasome activation in the stimulation of the IL-1-IL-22 axis by tumor cells.  
To see whether the identified CD4+ T cell fraction was also the target of this inflammasome 
activation, the experiments were replicated in MACS-enriched CD4+ T cells. 
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Figure 13: IL-22 induction by human breast cancer cell lines in CD4+ T cells can be 
antagonized through NLRP3 inhibition.  
Stimulation of MACS-enriched CD4+ T cells for six days with 50 % cell-free supernatant from 
H1339 in the presence of 50 µM CRID3. DMSO served as a negative control. IL-22 
concentration was quantified by ELISA. Values of four independent experiments are shown, 
with n = 7 different donors. Error bars represent SEM and statistical significance was 
calculated using two-sided Student’s t-tests. 
 
While not significant with the current number of repetitions, the data suggests that CD4+ T 
cells are indeed the main target of NLRP3 inflammasome activation. NLRP3 inhibition was 
not able to fully suppress IL-22 induction, pointing towards the existence of additional 
factors responsible for cytokine production in the IL-1-IL-22 axis.  
4.3.3 CD4+CD44+ memory T cells as main source of IL-22 
To further characterize the involved T cell population, naïve and memory CD4+ T cells 
were isolated. Purity of the CD4+ T cell fraction was between 84 and 98 %. The naïve CD4- 
splenocyte fraction contained less than 9 % CD4+CD44+ memory T cells, while the mixed 
CD4- contained at least 23 % CD4+CD44+ memory T cells (data not shown). 
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Figure 14: Human IL-22 production in naïve CD4+ T cells and CD4+CD44+ memory T 
cells after stimulation with human lung cancer cell line. 
Stimulation of total splenocytes, MACS-enriched naïve CD4+ T cells, and non-naïve T cells 
(CD4+CD44+ memory T cells with CD4- splenocytes) (2 x 106 per ml) for six days with cell-
free supernatant from A549 cell culture. IL-22 concentration was quantified by ELISA. Values 
of four independent experiments are shown, with n = 8 different donors. Error bars represent 
SEM and statistical significance was calculated using two-sided Student’s t-tests. 
 
It was found that isolated memory CD4+CD44+ T cells were proficient IL-22 producers in 
this model. The naïve CD4+ T cell-depleted fraction had lower levels of IL-22 secretion, but 
in contrast to the murine model partially retained their ability to produce IL-22. 
To investigate whether these memory T cells are also the target cells of the proposed 
mechanism via IL-1a and IL-1b, MACS-enriched cells were subsequently stimulated with 
recombinant proteins. 
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Figure 15: Human IL-22 production in naïve CD4+ T cells and CD4+CD44+ memory T 
cells after stimulation with recombinant proteins. 
Stimulation of total splenocytes, MACS-enriched naïve CD4+ T cells, and non-naïve T cells 
(CD4+CD44+ memory T cells with CD4- splenocytes) (2 x 106 per ml) for six days with 10 
ng/ml recombinant IL-1a and/or IL-1b. Values of three independent experiments are shown, 
with n = 5 different donors. Error bars represent SEM and statistical significance was 
calculated using two-sided Student’s t-tests. 
 
As seen in the murine model, the stimulatory effect of tumor supernatant on primarily 
CD4+CD44+ memory T cells can be replicated with recombinant proteins. In the human 
setting, both recombinant IL-1a and IL-1b seem to be similarly potent inducers of IL-22 
production from these memory T cells. Naïve CD4+ T cells are induced to produce some IL-
22, though significantly less than their memory counterparts.
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4.4 Ex vivo characterization of IL-22-producing cells in humans  
4.4.1 T helper cells are the main producers of IL-22 in primary breast cancer tissue 
To validate the existence of IL-22-producing T helper cell populations and to illustrate the 
relevance of the findings in human breast cancer, tumor samples of patients with breast 
cancer were analyzed for the presence of IL-22-producing cells. Single cell suspensions 
were stimulated for intracellular staining and IL-22-producing subpopulations were 
identified via flow cytometry. T helper cell subpopulations were defined as Th1 
(CD3+CD4+IL-17-IFNg+), Th17 (CD3+CD4+IL-17+IFNg-), and Th22 (CD3+CD4+IL-17-IFNg-); 
additional cell populations included CD3+CD8+, CD3+CD4-CD8-, and CD11b+ IL-22-
producing cells.  
On average, 0.23 % of the mononuclear cell fraction expressed IL-22 in breast cancer 
samples. Among these IL-22+ cells, the main fraction, accounting for 41 %, was of Th1 
phenotype, followed by Th22 and Th17 phenotypes (22 % and 9 %, respectively), making 
up almost ¾ of all IL-22+ cells. The remaining IL-22-producing cell populations included 
CD3+CD8+ (12 %), CD11b+ (12 %), and CD3+CD4-CD8- (2 %). Expression of IL-22 in 
breast cancer tissue was confirmed in protein lysates of the same tumor samples. On 
average, a concentration of 63.9 pg/mg protein IL-22 was measured. 
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Figure 16: Identification of IL-22-producing cells in primary breast cancer tissue via 
FACS.  
Single cell suspensions of breast cancer tissue were stimulated with PMA and ionomycin in 
the presence of brefeldin A and stained intracellularly for IL-22. Subsequently, they were 
analyzed via flow cytometry for IL-22 expression in Th1 (CD3+CD4+IFNg+), Th17 
(CD3+CD4+IL-17+), Th22 (CD3+CD4+IL-17-IFNg-), CD3+CD8+, CD3+CD4-CD8-, and CD11b+. 
Dead cells were excluded per live-dead staining (A to C). (D) Quantification of IL-22 
production in tumor lysates with ELISA. B to C represent n = 7 and D n = 11 patient samples. 
Error bars represent SEM and statistical significance was calculated using two-sided 
Student’s t-tests. 
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5 Discussion 
5.1 Summary of the mechanism of IL-22 induction in cancer 
IL-22 has been characterized as a tumor-promoting cytokine in previous literature. IL-22-
producing T cells have been found in lung and breast cancers, but also colorectal, gastric 
and pancreatic tumors (reviewed in: Lim and Savan 2014). In the majority of cases, IL-22 
expression was correlated with cancer development and progression and poor survival 
outcome. So far, few studies have addressed the exact mechanism by which IL-22 
expression is influenced by cancer cells. In addition, the classification of the target cells of 
this axis has been missing. 
This set of experiments characterizes a subset of IL-22-producing CD4+ T cells in mice and 
in humans which are induced by tumor cells in an IL-1-dependent manner. In the murine 
setting, CD4+ but not CD4-depleted T cells are capable of producing IL-22 when stimulated 
by tumor cell supernatants. With naïve CD4+ T cells shown to be irresponsive to 
stimulation, this project identified CD4+CD44+ memory T cells as the major IL-22-producing 
subset. The mechanism was shown to be dependent upon and replicable by IL-1 activation 
and conserved across different tumor entities. In murine cancer models, IL-1a was shown 
to be responsible for IL-22 production, whereas human cancer cell lines seem to induce IL-
22 through IL-1b via the activation of the NLRP3 inflammasome. In line, IL-22 content and 
tumor growth were reduced when IL-1 was neutralized in two different murine breast 
cancer models, pointing toward the potential use of IL-1- and IL-22-antagonists for cancer 
therapy.  
5.2 IL-1a secreted by tumor cells may stimulate IL-22 production from murine 
CD4+CD44+ memory T cells  
In the first set of experiments, murine CD4- cells did not secrete IL-22 upon stimulation, but 
non-naïve splenocytes, that is CD4- and CD4+CD44+ cells, produced significant cytokine 
levels. From this it can be concluded that the CD4+CD44+ subpopulation is most likely the 
major source of IL-22 and that IL-22 production is driven by reactivation of memory T cells 
rather than differentiation of naïve T cells.  
In the murine setting, it was shown that IL-1a is mainly responsible for this induction. IL-1a 
is expressed predominantly intracellularly or membrane-bound (Gross, et al. 2012, Orjalo, 
et al. 2009). Its precursor (pro-IL-1a) is activated through the protease Calpain into IL-1a 
N-terminal peptide (IL-1aNTP) (Voronov, et al. 2013). Its expression is upregulated through 
cell stress such as hypoxia and necrosis, which is common in fast-growing tumors both in 
vitro and in vivo (Cooper and Beasley 1999, Di Mitri, et al. 2014). Accordingly, IL-1a 
concentrations in tumor supernatants were strongly correlated with length of incubation 
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time (data not shown). The effects on IL-1R+ cells can be further enhanced by effect that IL-
1a can induce its own release from immune cells, causing positive feedback loops (Ghezzi 
and Dinarello 1988). So far, it has only been shown that murine NCR- ILC3 secrete IL-22 
upon stimulation with IL-1a (Hernandez, et al. 2015). While murine NCR- ILC3 also secrete 
IL-17 and low levels of IFNg, they are CD3-CD4- and localized primarily in the mucosa 
(Walker, et al. 2013). Given the identification of CD4+CD44+ memory T cells as the main 
target of IL-1a induced IL-22 production, these experiments seem to describe a new 
pathway.  
Naïve CD4+ T cells were unable to produce significant amounts of IL-22 upon stimulation 
with tumor cell supernatants containing IL-1a. This suggests that IL-1a stimulation does not 
share the same pathway with IL-6, a cytokine that is sufficient to induce IL-22 from naïve T 
cells in vitro in mouse through differentiation (Zheng, et al. 2007). Instead, the findings 
promote the hypothesis that IL-1a activates an existing pool of T helper cells by 
upregulating their IL-22 production. Nonetheless, low levels of IL-22 were secreted by 
naïve cells in most experiments. This was most likely due to either non-identified 
components released by tumor cells or direct stimulation by activated immune cells. The 
above experiments also cannot rule out that there exists some form of soluble or cell-to-cell 
interaction between these cell subpopulations. Naïve CD4+ T cells could still be a source of 
IL-22 after contact with stimulated CD4- or CD4+CD44+ cells. Moreover, suboptimal MACS 
purities in this experimental setup could have contributed to confounding factors.   
FACS analysis of stimulated splenocytes confirmed the presence of primarily Th22 cells, 
and smaller counts of Th1 and Th17 cells. In comparison to recombinant IL-1a, stimulation 
with tumor cell supernatants shifted the phenotype more towards Th22 cells, which is most 
likely due to the existence of additional factors such as TNFa (Duhen, et al. 2009). But 
although murine Th22 cells have been identified in literature, they are still not defined as an 
individual subset in vivo; according to literature, the main producers of murine IL-22 are 
Th17 cells. This mismatch might be explained by the fact that the presence of IL-17 can 
shape the role of IL-22 in cancer in vivo (Eyerich, et al. 2017). Moreover, IL-17 and IL-22 
are components of a highly redundant and regulated system involved in epithelial 
homeostasis, making it very difficult to predict the role of an individual cytokine in any given 
environment. Studies have also demonstrated plasticity of Th cell subsets, which appears 
to be dependent upon regulatory transcription factors that act as master regulators (Plank, 
et al. 2017).  
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5.3 CD4+CD44+ memory T cells are also responsible for IL-22 production in 
humans, but primarily upon IL-1b stimulation 
Similar to the murine setting, CD4+CD44+ memory T cells were identified as the primary 
source of IL-22 after stimulation with human tumor cell supernatant. In humans, IL-1b, more 
than IL-1a, was shown to be responsible for this induction. Naïve T cells were shown to be 
relatively irresponsive to IL-1 stimulation in terms of IL-22 production. This is in contrast 
with recent findings of significant polarization of the naïve T cell compartment in patients 
with psoriatic arthritis (Ezeonyeji, et al. 2017). One explanation why differentiation of naïve 
T cells was not observed in the experiments might be missing co-stimulation. In addition to 
IL-1b, Th17 cells, for example, are known to require additional stimulation through IL-6 and 
TGFb and interaction between the MHC class II and the cognate TCR for polarization 
(Liang, et al. 2006, Zheng, et al. 2007). Th22 cells, on the other hand, require IL-6 co-
stimulation (Duhen, et al. 2009). Hence, it cannot be fully determined whether IL-1b 
activates preexisting Th cells or drives their differentiation from naïve T cells.  
It was also shown that CD4+ cells co-secrete IL-17 and IFNg with IL-22, which is reversible 
through inhibition of the IL-1R-axis with anakinra (Voigt, et al. 2017). This may lead to the 
conclusion that a mixed Th1, Th17, and Th22 population produces IL-22 upon stimulation 
in an IL-1-dependent manner. Mechanistically, IL-1b could drive the differentiation of naïve 
T cells to Th1, Th17, and Th22 lineages, or IL-1b might be critical for activating or 
maintaining IL-22 from existing T helper cell subpopulations. In this set of experiments, IL-
22 production was only seen after reactivation of memory T cells. So far, this has only been 
shown in the context of C. albicans infections, where IL-22+CD4+ cells displayed a 
phenotype of both central and effector memory T cells (Liu, et al. 2009). As memory T cells 
can be heterogeneous in terms of effector functions and tissue-homing capacities, further 
analysis of chemokine receptor co-expression would be necessary to determine whether 
central or effector memory T cells are activated after IL-1 induction.  
Because cells were not sorted for CD3, human CD4+ ILCs cannot be excluded as a 
potential source of IL-22. CD4+CD3- ILCs have been described in literature to produce IL-22 
upon stimulation (Bekiaris, et al. 2013). However, in this experimental model it was shown 
that CD3- cells did not produce significant amounts of IL-22 using the proposed pathway 
(Voigt, et al. 2017). 
5.4 Mixed T helper cell populations are the main producers of IL-22 in primary 
human breast cancer tissue 
In literature, Th1 and Th17 cells have been identified in breast cancer and linked to dismal 
clinical outcomes (Gu-Trantien, et al. 2013). In this FACS analysis of primary human breast 
cancer tissue, a significant amount of IL-22 was detected via flow cytometry and protein 
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lysates. Th1 cells were identified as the main producers of IL-22 (41 %), followed by Th22 
and Th17 phenotypes (22 % and 9 %, respectively). In total, T helper cells made up almost 
¾ of all IL-22+ cells. The remaining IL-22-producing cell populations included CD3+CD8+ 
(12 %) and CD11b+ (12 %). This corresponds well with the in vitro analysis, where IFNg and 
IL-17 co-secretion with IL-22 was observed after stimulation with supernatants from cancer 
cell lines, most likely in an IL-1-dependent manner. It is also compatible with the findings 
generated in mice. The analysis would have further benefitted from comparison with 
healthy breast tissue. However, it was not possible to isolate sufficient number of cells from 
such tissue.  
5.5 Targeting the IL-1-IL-22 axis for cancer treatment 
The murine in vivo experiments link endogenous IL-1 activity to IL-22 production in two 
breast cancer models by showing downregulation of IL-22 positive cells in murine tissue 
after inhibition of endogenous IL-1 activity. This confirms the mechanism that was identified 
in vitro. Antagonizing IL-1 also led to significant retardation of tumor growth in both breast 
cancer models. While these findings are in line with prior literature, it has not yet been 
linked to the role of IL-22. IL-1 is detectable in human lung and breast cancer, as well as 
melanoma, head and neck, and colon cancers and its presence is usually associated with 
worse prognosis (Ye, et al. 2012). The experiments done here suggest a possible pathway: 
blockade of IL-1 reduces production of IL-22 in a specific T helper cell subset, thereby 
lessening its pro-tumorigenic effects leading to better tumor control. This indicates a 
potential role in cancer treatment in humans, either by blocking IL-1 or IL-22 directly.  
IL-1 antagonisation is already commonly used in a variety of diseases and has been 
classified as safe with a small spectrum of adverse effects (Dinarello 2010). Anakinra is 
currently tested in clinical trials in patients with pancreatic or metastatic breast cancer as an 
addition to chemotherapy regimens because it reduces peritumoral inflammation and 
cachexia. However, administration of anakinra has shortcomings such as a short half-life 
that necessitates high-dose daily injections as well as the simultaneous inhibition of both IL-
1a and IL-1b, two cytokines with different biology and distinct effects on immune responses 
in inflammation and tumorigenicity (Rider, et al. 2011). The experiments above suggest that 
in the human setting, IL-1b – activated through the NLRP3 inflammasome – plays a more 
prominent role in activation of the IL-1-IL-22 pathway. This finding is in line with results from 
the recent CANTOS trial, which evaluated the efficacy of the anti-IL-1b antibody 
canakinumab on reducing atherosclerosis. While not its primary endpoint, the study noted a 
significant reduction lung cancer incidence and mortality (Ridker, et al. 2017). The 
experiments of this thesis imply that blockade of IL-1b might have reduced IL-22 production 
in these patients, which could have slowed down cancer development and metastasis 
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formation. Further evaluations, preferably in respect to IL-22 secretion and T helper cell 
subsets in canakinumab treated patients, are necessary to expose the pathway underlying 
this interesting finding.  
The experiments also show that the NLRP3 inflammasome is necessary for the activation 
of the IL-1-IL-22 axis. Thus, another therapeutic approach could be the inhibition of IL-1b 
processing through specific inflammasome inhibitors. Recently, IL-1b released via NLRP3 
has been demonstrated to be pro-tumorigenic by promoting metastasis and 
lymphangiogenesis (Weichand, et al. 2017). NLRP3 inhibitors are currently tested for 
treatment of inflammatory diseases and could turn out to be promising cancer therapies 
once their efficacy in decreasing IL-1b production in vivo has been demonstrated (Coll, et 
al. 2015).  
Finally, direct inhibition of IL-22-IL-22-R signaling without IL-1 targeting should be assessed 
in terms of anti-tumoral effects in humans. Anti-IL-22 antibodies have already demonstrated 
positive effects in inflammatory diseases such as psoriasis and atopic dermatitis, again 
showing limited side effects. Larger trials, preferably with a focus on cancer development 
and spreading, are necessary to see if data from the CANTOS trial can be replicated by 
direct IL-22 inhibition. IL-22-BP, the endogenous antagonist of IL-22, also appears to be an 
attractive choice for targeting IL-22. However, further verification of its biological properties 
is necessary, as some studies have shown that IL-22BP may lead to stabilization of IL-22 
(Jiang, et al. 2011). Finally, direct inhibition of IL-22-Ra1 should be evaluated. Direct 
blockade of IL-22-Ra1 is interesting because its expression is primarily limited to epithelial 
cells and potentially also reduces the pro-tumoral effects of IL-20 and IL-24. IL-22 
antagonists can therefore potentially spare patients from adverse effects, which often lead 
to dangerous states of immunodeficiency or severe autoimmune disorders (reviewed in: 
Lim and Savan 2014).  
When comparing different treatment approaches, heterogeneity of and responses by tumor 
cells need to be carefully evaluated. For instance, it was recently found that IL-1 is an 
important inflammatory driver in pancreatic cancer, but IL-1 inhibition with anakinra was 
unable to inhibit tumor growth of cells with EMT phenotype due to continuous activation of 
IL-6 by EMT transcription factors (Siddiqui, et al. 2018).  
5.6 Conclusion and perspectives 
In summary, this thesis describes a previously unknown mechanism through which cancer 
cells induce IL-22 and characterizes the target cell as memory T cells of primarily Th22 
subtype (see Figure 17). Through the release of IL-1a in mice or the induction of IL-1b via 
the NLRP3 inflammasome in humans, IL-22 production is upregulated in the tumor 
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microenvironment. In the murine system, IL-1a and to a lesser extent IL-23 release from 
(hypoxic) tumor cells activates memory T cells, which leads to IL-22 secretion from T cells 
that are primarily of Th22, but also Th1 and Th17 subtype. In the human setting, the 
NLRP3 inflammasome is activated in memory T cells, either directly through cancer cells or 
indirectly via myeloid cells. Subsequent IL-1b release acts on memory T cells to produce 
IL-22 by either reactivating pre-existing or inducing differentiation into a mixed Th cell 
population. 
In this context, IL-22 can be seen as a double-edged sword: by increasing cell proliferation, 
migration and angiogenesis, it is an important cytokine for tissue regeneration and host 
defense, but its functions can be hijacked by cancer cells to enhance progression. Together 
with the results from in vivo experiments, the findings support the idea of developing 
therapeutic approaches that intervene in the IL-1-IL-22 axis in cancer and provide a 
rationale for targeting various points along this axis. What remains elusive, however, is the 
exact mechanism which links IL-22 to worse prognosis in cancer. Given its role as a 
complex homeostatic cytokine, it is likely that pathways differ across cancer entities and 
stages of disease, including induction of stemness, EMT, angiogenesis and proliferation. 
Uncovering these mechanisms would help to understand the links between cancer and the 
immune system and offer further treatment options.  
 
Figure 17: Schematic model of the IL-1-IL-22 axis (modified from: Voigt, et al. 2017). 
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6 Summary 
 
Interleukin-22 (IL-22) is a unique cytokine which is secreted exclusively by cells of 
hematopoietic origin, but its direct effects are restricted to interleukin-22-receptor (IL-22-R) 
expressing epithelial cells. By facilitating cross-talk between hematopoietic and non-
hematopoietic cells, IL-22 plays an important role in tissue regeneration, repair and 
epithelial defense. Dysfunction of the IL-22-IL-22-R axis has been linked to several 
autoimmune diseases such as psoriasis or inflammatory bowel diseases. In cancer, IL-22 
has been suggested to promote tumorigenesis, induction of stemness and metastasis 
formation. However, neither the exact mechanism of induction nor the exact cellular 
sources have been characterized for lung and breast cancers. 
In previous analyses our group has shown that cancer cells can directly induce IL-22 
production from murine and human immune cells. We could demonstrate that this process 
is driven by IL-1a in murine and IL-1b in human immune cells. We could also show that 
these cytokines primarily acted on CD3+ T cells and mediated IL-22 production via the 
transcription factors AhR and RORgt. To further elucidate this pathway, we wanted to fully 
characterize the T cell subpopulation and confirm the mechanism by which cancer cells 
induce IL-22 secretion from these target cells. We also aimed to demonstrate the potential 
therapeutic benefits from intervening in the IL-1-IL-22 axis in cancer therapy.  
This thesis identified CD4+CD44+ memory T cells as the major IL-22-producing subset. The 
mechanism was shown to be dependent upon and replicable by IL-1 activation and 
conserved across different tumor entities. In murine cancer models, IL-1a was shown to be 
responsible for IL-22 production from memory T cells, whereas human cancer cell lines 
appear to induce IL-22 through IL-1b via the activation of the NLRP3 inflammasome. It was 
concluded that IL-1 secreted by tumor cells promotes IL-22 production by either activating a 
pre-existing Th cell population or inducing differentiation of a mixed Th cell population, with 
a majority of the cells exhibiting a Th22 phenotype. Th22 cells were also shown to be the 
main source of IL-22 in primary breast cancer tissue using FACS analysis.  
In line with these findings, IL-22 content and tumor growth were reduced when IL-1a and 
IL-1b were neutralized in two different murine breast cancer models. This points towards 
the potential use of IL-1- and IL-22-antagonists for cancer therapy.  
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7 Zusammenfassung 
 
Interleukin-22 (IL-22) ist ein besonderes Zytokin, dessen Effekte auf Interleukin-22-
Rezeptor (IL-22-R)-tragende Zellen epithelialen Ursprungs begrenzt ist. Es ermöglicht die 
Kommunikation zwischen hämatopoietischen und nicht-hämatopoietischen Zellen und 
spielt eine wichtige Rolle bei der Regeneration und Heilung von Gewebe sowie der 
epithelialen Abwehr. Störungen in der IL-22-IL-22-R-Achse sind bei einigen 
Autoimmunerkrankungen wie Psoriasis oder chronisch-entzündlichen Darmerkrankungen 
nachweisbar. Im Zusammenhang mit Krebserkrankungen wurde die tumorfördernde Rolle 
durch verstärkte Tumorgenese, Aktivierung von Stammzellen und Förderung der 
Metastasierung beschrieben. Bisher wurde jedoch weder der genaue 
Induktionsmechanismus von IL-22 noch die produzierende Zellpopulation bei Brust- und 
Lungenkrebs genau charakterisiert.   
In bisherigen Untersuchungen unserer Arbeitsgruppe konnte gezeigt werden, dass 
Tumorzellen die IL-22-Produktion in murinen und humanen Immunzellen induzieren 
können. Wir konnten zudem zeigen, dass dies durch IL-1a in murinen und IL-1b in 
humanen Immunzellen geschieht. Des Weiteren konnte in Versuchen gezeigt werden, dass 
diese Zytokine vor allem auf CD3+ T Zellen wirken und dass die IL-22-Produktion durch die 
Transkriptionsfaktoren AhR und RORgt reguliert wird. Auf dieser Basis sollte im Folgenden 
die IL-22 produzierende T-Zell-Subpopulation genau charakterisiert und der Mechanismus 
im humanen Modell näher untersucht werden. Darüber hinaus sollte durch Tierversuche 
der therapeutische Nutzen eines Eingriffs in die IL-1-IL-22-Achse aufgezeigt werden. 
Die vorliegende Arbeit identifizierte CD4+CD44+ T-Gedächtniszellen als Hauptproduzenten 
von IL-22. Der Induktionsmechanismus war in allen getesteten Brust- und 
Lungenkrebsmodellen abhängig von IL-1. Es konnte gezeigt werden, dass im murinen 
Modell IL-1a die IL-22-Produktion durch Gedächtnis T-Zellen induziert, wohingegen im 
humanen Modell IL-1b über die Aktivierung des NLRP3-Inflammasoms verantwortlich ist. 
Daraus konnte geschlossen werden, dass durch Tumorzellen sezerniertes IL-1 die IL-22-
Produktion durch Reaktivierung bereits vorhandener oder Induktion der Differenzierung 
einer gemischten T-Helferzell-Population mit einem überwiegend Th22-Phänotyp fördert. 
Th22-Zellen konnten zudem als Hauptproduzenten im primären Brustkrebsgewebe mittels 
FACS Analyse identifiziert werden.  
Darauf aufbauend konnte gezeigt werden, dass nicht nur die Menge von IL-22, sondern 
auch das Tumorwachstum durch Hemmung von IL-1 im Tiermodell reduziert werden 
konnte. Dies deutet darauf hin, dass die Inhibition von IL-1 oder IL-22 eine Strategie in der 
Tumortherapie darstellen könnte. 
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9 Appendices 
9.1 Abbreviations 
Ab  antibody 
AhR  aryl hydrocarbon receptor 
anti-IL-1-R interleukin-1-receptor neutralizing antibody 
APC  allophycocyanin 
ATCC  American Type Culture Collection 
 
BP  binding protein 
BSA  bovine serum albumin  
 
CCL  chemokine ligand 
CD  cluster of differentiation 
COPD  chronic obstructive pulmonary disease 
Cy  cyanin 
 
DC  dendritic cell 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
 
ELISA  enzyme-linked immunosorbent assay 
EMT  epithelial-mesenchymal transition 
ERK  extracellular signal-regulated kinase 
 
FACS  fluorescence-activated cell sorting 
FBS  fetal bovine serum 
FITC  fluorescein isothiocyanate 
FSC  forward scatter 
 
IBD  inflammatory bowel disease 
IFN  interferon 
IGF-1  insulin-like growth factor 1 
IL  interleukin 
IL-22-Ra1 interleukin-22-receptor-1 a chain 
ILC  innate lymphoid cell 
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iNK  immature NK cell 
iNKT  invariant NKT cell 
i. p.  intraperitoneally 
 
JAK  Janus kinase 
 
LANA  latency-associated nuclear antigen 
LTi cell  lymphoid tissue inducer cell 
 
MAb  monoclonal Antibody 
MACS  magnetic-activated cell sorting 
MAPK  mitogen-activated protein kinase 
MHC  major histocompatibility complex 
mRNA  messenger ribonucleic acid 
mTOR  mammalian target of rapamycin 
 
N. d.  not detectable 
n. s.  not significant 
NEAA  non-essential amino acids 
NK cell  natural killer cell 
NKT cell natural killer T cell 
NLRP3  Nod-like receptor protein 3 
NSCLC non-small cell lung cancer 
NTP  N-terminal peptide 
 
P3K/Akt phosphoinositide-3 kinase/Akt 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate-buffered saline 
PE  phycoerythrin 
PerCP  peridinin chlorophyll protein complex 
PMA  phorbol-12 myristate-13 acetate   
 
Rec.  recombinant 
RNA  ribonucleic acid 
ROR  retinoic acid-related orphan receptor 
RPMI  Roswell Park Memorial Institute 
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SCLC  small cell lung cancer 
SEM  standard error of mean 
SNP  single nucleotide polymorphism 
STAT  signal transducer and activator of transcription 
STR  short tandem repeats 
 
Tc  cytotoxic T cell 
TCR  T cell receptor 
TEMED tetramethylethylenediamine 
TGF  tumor growth factor 
Th  T helper cell 
TIL  tumor infiltrated leukocyte 
TLR  Toll-like receptor  
TNF  tumor necrosis factor 
TYK  tyrosine kinase 
 
VEGF  vascular endothelial growth factor 
VLE  very low endotoxin 
 
WT  wild type  
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